Sales & Marketing

Clinical trials report Izervay slowed disease progression as early as six months.

Extension complements pharmaceutical’s total lab solutions portfolio.

Decision comes amid recommendation from agency’s Committee for Medicinal Products for Human Use.

Treatment indicated for adult patients with metastatic colorectal cancer.

Deal comes amid companies’ bankruptcy filings.

Addition expected to provide approximately $1 billion in capital.

Agreement includes request to dismiss pending lawsuit.

Treatment is the first of its kind to focus on endometrial cancer.

Industry veteran Charles Pirraglia demystifies the journey of bringing life-changing therapies to the Canadian market, from understanding drug pricing to navigating direct-to-consumer advertising rules.

New deal to focus on commercialization efforts in Latin America.

Total deal expected to be worth approximately $7.3 billion.

Partnership intended to enhance development plan of biopharma’s drug candidate.

Research discovered no new safety signals.

Balfaxar indicated for restoration of blood coagulation.

Medicine indicated for adults and pediatric patients aged two and older.

Medicine developed in collaboration between Boehringer Ingelheim and Eli Lilly.

Treatment is the first approved for eyelid disease.

Collaboration aims to treat hypertension in patients with high cardiovascular risk.

Layoff comes amid preparations for Leqembi launch.

Navigating the challenging landscape of pharmaceutical naming—where a name must meet regulatory approval, clear trademark hurdles, and capture market attention all at once.

Collaboration intended to enable faster market delivery time for life-threatening disease medications.

Approval of Vanflyta comes nearly four years after initial rejection.

Move likely to be completed by early next year.

Collaboration aims to help pharmaceuticals drive efficiencies and business value.

Research to focus on multiple immunological and inflammatory indications.